Biosimilars Would Have Reimbursement Parity With Innovators Under Health Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand industry supports amendment in Senate Finance Committee that is sponsored by Sen. Schumer but is not as aggressive as the coding change option offered by CBO.
You may also be interested in...
Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Rep. Henry Waxman, D-Calif., can perhaps take some comfort in the fact that his defeat on follow-on biologics means his broader health reform legislation may have a greater chance of passage
Follow-On Biologics Coding Tweaks Could Raise Savings By 30% – CBO
Giving a follow-on biologic the same reimbursement code as its brand name counterpart would increase the savings from FOBs by 30 percent for the federal government's mandatory health care programs, the Congressional Budget Office estimates
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.